p53 mutations are rare events in recurrent cervical cancer

被引:18
作者
Denk, C
Butz, K
Schneider, A
Dürst, M
Hoppe-Seyler, F
机构
[1] Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-69120 Heidelberg, Germany
[2] Univ Jena, Frauenklin, D-07740 Jena, Germany
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2001年 / 79卷 / 5-6期
关键词
p53; human papillomavirus; cervical cancer; yeast functional assay;
D O I
10.1007/s001090100191
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Mutations of the p53 gene have been shown to be associated with aggressive growth behavior and increased recurrence rates for certain tumors. Primary cervical cancers contain oncogenic human papillomaviruses (HPV) in more than 90% of cases and usually possess wild-type p53 alleles. Cervical cancer cells contain detectable levels of functional p53 protein despite of the expression of the HPV E6 protein, which can induce p53 degradation. Thus, inactivation of p53 by somatic mutation should have functional consequences in HPV-positive cancers. We investigated whether p53 mutations play a role in the recurrence of the disease by analyzing p53 status in 18 biopsy specimens from recurrent cervical cancers. Only one of these (5.6%) contained a p53 mutation, as assessed by a sensitive yeast functional assay that detects mutations of the p53 mRNA between codons 52 and 364. These results indicate that p53 mutations are rare events in recurrent cervical carcinomas, and that somatic mutations of p53 do not provide cervical cancer cells with a selective growth advantage for recurrence.
引用
收藏
页码:283 / 288
页数:6
相关论文
共 40 条
[1]   p14ARF links the tumour suppressors RB and p53 [J].
Bates, S ;
Phillips, AC ;
Clark, PA ;
Stott, F ;
Peters, G ;
Ludwig, RL ;
Vousden, KH .
NATURE, 1998, 395 (6698) :124-125
[2]   Expression and mutational analysis of P53 in stage IB and IIA cervical cancers [J].
Benjamin, I ;
Saigo, P ;
Finstad, C ;
Takahashi, H ;
Federici, M ;
Rubin, SC ;
Boyd, J .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 175 (05) :1266-1271
[3]   P53 and angiogenesis [J].
Bouck, N .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1287 (01) :63-66
[4]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[5]   P53 MUTATIONS IN CERVICAL CARCINOGENESIS LOW-FREQUENCY AND LACK OF CORRELATION WITH HUMAN PAPILLOMAVIRUS STATUS [J].
BUSBYEARLE, RMC ;
STEEL, CM ;
WILLIAMS, ARW ;
COHEN, B ;
BIRD, CC .
BRITISH JOURNAL OF CANCER, 1994, 69 (04) :732-737
[6]   Induction of the p53-target gene GADD45 in HPV-positive cancer cells [J].
Butz, K ;
Whitaker, N ;
Denk, C ;
Ullmann, A ;
Geisen, C ;
Hoppe-Seyler, F .
ONCOGENE, 1999, 18 (14) :2381-2386
[7]  
BUTZ K, 1995, ONCOGENE, V10, P927
[8]  
Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO
[9]  
2-2
[10]  
Chappuis PO, 1999, INT J CANCER, V84, P587, DOI 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO